ORGO Q1 2022 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$97M-5.3% YoY

Gross Profit

$72M74.2% margin

Operating Income

-$128,000-0.1% margin

Net Income

-$913,000-0.9% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-24.5%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$5M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$436M

Total Liabilities

$193M

Stockholders' Equity

$243M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$97M	$103M	-5.3%
Gross Profit	$72M	$77M	-6.5%
Operating Income	-$128,000	$13M	-101.0%
Net Income	-$913,000	$10M	-109.2%

Revenue Segments

Advanced Wound care

$91M93%

Surgical and Sports Medicine

$7M7%